From the ∗Department of Population Health Sciences, School of Public Health, Georgia State University
†Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA
Acknowledgments: The authors would like to acknowledge the dedication and hard work of contributing sites to the Gonococcal Isolate Surveillance Project (GISP), GISP regional labs and GC reference labs in AR Lab Network, and GISP team members at the CDC. The authors thank Hillard Weinstock, Elizabeth Torrone, and Ian Spicknall for feedback, Alesia Harvey and Eloisa Llata for assistance with obtaining and interpreting data, and Mark Stenger for discussion concerning weighting procedures.
Conflicts of Interest: Office of Management and Budget/Centers for Disease Control and Prevention Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Sources of Funding: This work was completed while the first author participated in an Intergovernmental Personnel Act agreement for a temporary part-time assignment to the Centers for Disease Control and Prevention from Georgia State University (20IPA2013636).
Correspondence: Karen E. Nielsen, PhD, Department of Population Health Sciences, School of Public Health, Georgia State University, Suite 457, 140 Decatur Street, Atlanta, GA 30303. E-mail: [email protected].
Received for publication September 19, 2022, and accepted December 2, 2022.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (http://www.stdjournal.com).
